The content on this site is intended for healthcare professionals only
Dr Ghia speaks with ecancer at EHA 23 about the design and early findings of the phase II CAPTIVATE study, treating CLL patients with ibrutinib and venetoclax.
He describes the sequencing of the two drugs, which are both approved as monotherapy, and assessments in place for depth of response.
Dr Ghia summarises some preliminary data, which indicate a good rate of response, and outlines when further results will be available.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Best practice in precision medicine for prostate cancer
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Addressing the rise of multiple myeloma in Rwanda
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
